Folkert J. van Kemenade

Erasmus University Rotterdam
Country flagNetherlands

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Loss to follow‐up (LTFU) within cervical screening programmes can result in missed clinically relevant lesions, potentially reducing programme effectiveness. To examine the health impact of losing women during the screening process, we determined the proportion of women LTFU per step of the Dutch hrHPV‐based screening programme. We then determined the probability of being LTFU by age, screening history and sampling method (self‐ or clinician‐sampled) using logistic regression analysis. Finally, we estimated the number of missed CIN2+/3+ lesions per LTFU moment by using the CIN‐risk in women compliant with follow‐up. Data from the Dutch nationwide pathology databank (Palga) was used. Women eligible for screening in 2017 and 2018 were included ( N = 840,428). For clinician collected (CC) samples, the highest proportion LTFU was found following ‘referral advice for colposcopy’ (5.5% after indirect referral; 3.8% after direct referral). For self‐sampling, the highest proportions LTFU were found following the advice for repeat cytology (13.6%) and after referral advice for colposcopy (8.2% after indirect referral; 4.3% after direct referral). Self‐sampling users and women with no screening history had a higher LTFU‐risk (OR: 3.87, CI: 3.55–4.23; OR: 1.39, CI: 1.20–1.61) compared to women that used CC sampling and women that have been screened before, respectively. Of all women LTFU in 2017/18, the total number of potentially missed CIN2+ was 844 (21% of women LTFU). Most lesions were missed after ‘direct referral for colposcopy’ ( N = 462, 11.5% of women LTFU). So, this indicates a gap between the screening programme and clinical care which requires further attention, by improving monitoring of patients after referral.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

Nanda Horeweg

Assistant Professor

Leiden University Medical Center

NETHERLANDS
View details

Frank Hoentjen

Associate professor

University of Alberta

CANADA
View details

Harm Haak

Maastricht University Medical Centre

NETHERLANDS
View details

Heleen J van Beekhuizen

Erasmus University Rotterdam

NETHERLANDS
View details

Helena C van Doorn

university medical center rotterdam

NETHERLANDS
View details

Leo Hofland

Erasmus University Rotterdam

NETHERLANDS
View details

Ruud Bekkers

professor in gynecologic oncology

University of Maastricht

NETHERLANDS
View details

I. M. C. M. de Kok

-

NETHERLANDS
View details

Caroline Muntinga

University of Maastricht

NETHERLANDS
View details

Lucie de Jonge

Erasmus University Rotterdam

NETHERLANDS
View details

Nicole Erler

Erasmus University Rotterdam

NETHERLANDS
View details

Iris Lansdorp-Vogelaar

Associate Professor

Erasmus University Medical Center

NETHERLANDS
View details

Evelien Dekker

Professor

Amsterdam University Medical Centers

NETHERLANDS
View details

Manon C W Spaander

-

NETHERLANDS
View details

Ralf van de Laar

Erasmus University Rotterdam

NETHERLANDS
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.